Infanrix Hexa

Infanrix Hexa Uses, Dosage, Side Effects, Food Interaction and all others data.

A combination of 6 vaccines- diphtheria-tetanus-pertussis, hepatitis B, inactivated polio vaccine and hemophilus influenzae type b vaccine.1 dose (0.5 ml) contains:

Diphtheria toxoid (adsorbed on aluminium hydroxide): not less than 30 IU.Tetanus toxoid (adsorbed on aluminium hydroxide): not less than 40 IU.Bordetella pertussis antigens Pertussis toxoid (adsorbed on aluminium hydroxide): 25 mcgFilamentous haemagglutinin (adsorbed on alum, hydroxide): 25 mcgPertactin (adsorbed on al. hydroxide): 8 mcgHepatitis B surface antigen (produced in yeast cells/ adsorbed on alum, phosphate): 10 mcgPoliovirus (inactivated) propagated in VERO cells-Type 1 (Mahoney strain): 40 D-antigen unit

-Type 2 (MEF-1 strain): 8 D-antigen unit

-Type 3 (Saukett strain): 32 D-antigen unit

Haemophilus influenzae type b polysaccharide: 10 mcgConjugated to tetanus toxoid as carrier protein: 20- 40 mcg.The DTPa-HBV-IPV component is presented as a turbid white suspension. Upon storage, a white deposit and clear supernatant can be observed. The Hib component is presented as a white powder. The vaccine is available as- powder and suspension for suspension for deep i.m injection

Infanrix Hexa
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Infanrix Hexa
Generic	DPT + Poliomyelitis + Haemophilus Influenzae Type B (HIB) + Hepatitis B Conjugate Vaccines
Weight	0.5ml, 30iu/0.5ml, 25mcg/0.5ml, 40iu/0.5ml
Type	Injection
Therapeutic Class	Vaccines, Anti-sera & Immunoglobulin
Manufacturer	Glaxosmithkline
Available Country	Bangladesh, Pakistan
Last Updated:	September 19, 2023 at 7:00 am

Uses

This combined vaccine (6 vaccines) is used for primary & booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and haemophilus influenzae type b.

Dosage

Infanrix Hexa dosage

Primary vaccination: The primary vaccination schedule consists of 3 doses of 0.5 ml (e.g at 2,3,4 months; 3,4, 5 months; 2, 4, 6 months) or 2 doses (e.g at 3, 5 months). There should be an interval of at least 1 month between doses. The Expanded program on immunisation schedule (at 6,10,14 weeks of age) may only be used if a dose of hepatitis B vaccine has been given at birth.

Locally established immunoprophylactic measures against hepatitis B should be maintained. Where a dose of hepatitis B vaccine is given at birth, this combined vaccine can be used as a replacement for supplementary doses of hepatitis B vaccine from the age of 6 weeks. If a second dose of hepatitis B vaccine is required before this age, monovalent hepatitis B vaccine should be used.

Booster vaccination: Alter a vaccination with 2 doses (e.g at 3, 5 months) of ‘this vaccine’ a booster dose must be given at least 6 months after the last priming dose, preferably between 11 and 13 months of age.

After vaccination with 3 doses (e.g at 2,3,4 months; 3,4, 5 months; 2,4, 6 months) of this vaccine a booster dose may be given at least 6 months after the last priming dose and preferably before 18 months of age.Booster doses should be given in accordance with the official recommendations. This vaccine can be considered for the booster if the composition is in accordance with the official recommendations.

Other combinations of antigens have been studied in clinical trials following primary vaccination with this vaccine and may be used for a booster dose: diphtheria, tetanus, acellular pertussis (DTPa), or diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b (DTPa+Hib), or diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, Haemophilus influenzae type b (DTPa-IPV+Hib), or diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliomyelitis, Haemophilus influenzae type b (DTPa-HBV-IPV+Hib).

This vaccine should be administered by deep intramuscular injection.

Side Effects

Loss of appetite; irritability, abnormal crying, restlessness, nervousness; vomiting, diarrhea; pruritus. Fever, fatigue, inj site reactions including pain, redness, local swelling & induration.

Precaution

Hypersensitivity to neomycin & polymyxin. Do not administer intravascularly or intradermally. Postpone vaccination in patients w/ acute severe febrile illness.

Temp >40°C, collapse or shock-like state, persistent & inconsolable crying lasting >3 hr w/in 48 hr of vaccination. Convulsions with or without fever w/in 3 days of vaccination. Progressive neurological disorders including infantile spasms, uncontrolled epilepsy or progressive encephalopathy. Anaphylactic event & syncope may occur. Thrombocytopenia or bleeding disorder. History of febrile convulsions. Consider risk of apnea & resp monitoring for 48-72 hr in very premature infants (>28 wk of gestation) & those w/ history of resp immaturity. False +ve urine tests for HIB infection w/in 1 -2 wk after vaccination.